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Abstract
NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly
immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8+ T cell epitope, NY-ESO-188–96
(LEFYLAMPF) and compared its direct- and cross-presentation to that of the reported NY-ESO-1157–165 epitope restricted to
HLA-A*0201. Although both epitopes were readily cross-presented by DCs exposed to various forms of full-length NY-ESO-1
antigen, remarkably NY-ESO-188–96 is much more efficiently cross-presented from the soluble form, than NY-ESO-1157–165.
On the other hand, NY-ESO-1157–165 is efficiently presented by NY-ESO-1-expressing tumor cells and its presentation was not
enhanced by IFN-c treatment, which induced immunoproteasome as demonstrated by Western blots and functionally a
decreased presentation of Melan A26–35; whereas NY-ESO-188–96 was very inefficiently presented by the same tumor cell
lines, except for one that expressed high level of immunoproteasome. It was only presented when the tumor cells were first
IFN-c treated, followed by infection with recombinant vaccinia virus encoding NY-ESO-1, which dramatically increased NY-
ESO-1 expression. These data indicate that the presentation of NY-ESO-188–96 is immunoproteasome dependent.
Furthermore, a survey was conducted on multiple samples collected from HLA-B18+ melanoma patients. Surprisingly, all the
detectable responses to NY-ESO-188–96 from patients, including those who received NY-ESO-1 ISCOMATRIX
TM vaccine were
induced spontaneously. Taken together, these results imply that some epitopes can be inefficiently presented by tumor
cells although the corresponding CD8+ T cell responses are efficiently primed in vivo by DCs cross-presenting these
epitopes. The potential implications for cancer vaccine strategies are further discussed.
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Introduction
Professional antigen presenting cells (APC) such as dendritic
cells (DCs) are responsible for the initial induction, also referred to
as priming, of the cellular immune response to pathogens [1] as
well as tumors [2]. Various forms of tumor antigens, soluble, cell-
bound or complexed to specific antibody as immune-complex (IC),
are taken up by DCs and their CD8+ T cell (TCD8+) epitopes are
then presented to antigen-specific TCD8+ - a process called cross-
presentation [3,4,5]. Various strategies targeting cross-presenta-
tion by DCs (such as ISCOMATRIXTM adjuvant [6]) or
stimulating DC differentiation and maturation (e.g. by tumor cells
expressing GM-CSF and CD40L [7]) have been developed and
trialed clinically. The validity of such vaccination strategies hinges
on the assumption that tumor cells display the same epitopes that
are generated by the targeted DCs.
It is well established that mature DCs express the immunopro-
teasome constitutively [8]. However under non-immune condi-
tions, tumor cells and other somatic cells, express the constitutive
proteasome and are generally considered unable to initiate T cell
responses via direct presentation due to the lack of co-stimulatory
molecule expression [9]. The two types of proteasomes have been
shown to cleave peptides with different specificities in vitro [10,11],
which is thought to lead to altered T cell selection and immune
response in vivo to viral antigens [12,13,14], self antigens [11], as
well as tumor antigens [15].
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However, none of these studies specifically addressed cross-
presentation by DCs, which is more relevant in anti-tumor
immunity. It has been demonstrated in mouse models that direct
antigen presentation requires continuous antigen synthesis and is
typically enhanced with increased intracellular protein degrada-
tion [16,17]; on the contrary, efficient cross-presentation relies on
more stable proteins, large protein fragments [18] or ongoing
protein synthesis in the antigen-donating cells [19]. It is also
known that the two presentation pathways differ markedly [20].
These differences imply that DC and tumor cell present different
repertoires of peptides and some of the differences may lead to
disparate patterns of immune responses. For example, if given
tumor antigen epitopes are not cross-presented by DCs, related
immune responses may not be primed, even when tumor cells
abundantly and directly present these epitopes. This scenario
could provide a novel opportunity for vaccine intervention.
Indeed, we have recently shown that TCD8+ specific for the
HLA-B7-resticted NY-ESO-160–72 are rarely primed under
physiological conditions, yet are easily detected in melanoma
patients vaccinated with NY-ESO-1 formulated with ISCOMA-
TRIXTM, a saponin and cholesterol based adjuvant that has been
shown to target exogenous antigen to the cytosol to enable antigen
cross-presentation [21]. Conversely, if tumor antigenic epitopes
are cross-presented by DCs, but not directly presented by tumor
cells, irrelevant immune responses may be primed. Such responses
may not be directly protective, because the activated, tumor
antigen-specific TCD8+ would not recognize and eliminate these
tumor cells. Furthermore, the elicited TCD8+ could even be
detrimental when they are immunodominant, because they may
eliminate the cross-presenting DCs upon subsequent vaccinations
and thus significantly impair priming of other subdominant T cell
responses that may be beneficial to the host, a phenomenon called
immunodomination [22,23]. This scenario has potentially high
clinical significance because it is difficult to alter antigen
presentation by tumor cells in vivo. To date, few studies
demonstrated such difference between direct- and cross-presenta-
tion for the same TCD8+ epitopes.
NY-ESO-1 is a cancer testis (CT) antigen expressed by a wide
range of human tumors [24,25,26]. It is highly immunogenic both
in natural disease and in vaccination settings [6,27]. To
understand the underlying mechanisms for such outstanding
immunogenicity, the antigen processing and presentation proper-
ties of the NY-ESO-1 ISCOMATRIXTM vaccine and other
formulations of NY-ESO-1 antigen have been characterized in our
laboratories [3,28]. In the present study, we identified and
characterized another unique NY-ESO-1 epitope restricted to
HLA-B*1801 (hereafter HLA-B18) from a patient who participat-
ed in our NY-ESO-1 ISCOMATRIXTM vaccine trial [6]. The
novel T cell epitope, NY-ESO-188–96 (LEFYLAMPF), was shown
to elicit immunodominant responses and to be efficiently cross-
presented by full-length, soluble NY-ESO-1 pulsed monocyte
derived dendritic cells (MoDCs). However, this epitope is poorly
directly presented by tumor cells expressing both HLA-B18 and
NY-ESO-1, unless the immunoproteasome is expressed at high
level. Our results demonstrate that not all immunodominant
responses may play a direct role to eliminate tumor cells.
Results
Identification and Characterization of a Novel TCD8+
Epitope NY-ESO-188–96 Presented by HLA-B18
In order to examine the T cell mediated immune response to
NY-ESO-1, a systematic 18 mer peptide screen was performed
using peripheral blood mononuclear cells (PBMCs) from melano-
ma patient 8 previously vaccinated with NY-ESO-1 ISCOMA-
TRIXTM vaccine [6]. To preserve PBMC samples, pooled 18 mer
peptides were used to stimulate NY-ESO-1 specific T cells in the
PBMCs. The cultures containing amplified NY-ESO-1-specific
TCD8+ were subsequently assessed with individual 18 mer
peptides. Our screen showed that the patient had an immunodo-
minant response to NY-ESO-1 in the 79–96 region (Figure 1A).
Using overlapping 13mer and shorter peptides within the 79–96
sequence in conjunction with peptide prediction algorithms, we
narrowed down the likely minimum epitope to 88–96. To confirm
this, the NY-ESO-188–96 peptide and two other shorter peptides
were synthesized and tested by the antigen-specific T cell line. As
shown in Figure 1B, at 1028 M and in the absence of serum
proteases, NY-ESO-188–96 was able to activate the antigen-specific
TCD8+, but the two peptides with a single amino acid truncation at
either end failed to do so, indicating that NY-ESO-188–96 is the
minimal epitope. Typically 50% of specific T cells within such a
TCD8+ line would be activated by as little NY-ESO-188–96 peptide
as 1029 M (Figure. 1C).
To characterize which HLA class I allele bound the NY-ESO-
188–96 peptide, homozygous lymphoblastoid cell lines (LCL)
sharing HLA molecule with patient 8, namely 9010, 9039, and
9063, were pulsed with NY-ESO-188–96, washed, and co-cultured
with TCD8+ specific for NY-ESO-188–96. Clearly these TCD8+
produced IFN-c only when co-cultured with peptide pulsed LCL
9039 (Figure. 1D), which shared HLA-B18 and HLA-Cw5 with
patient 8. However, LCL 9063 also expressed HLA-Cw5 and was
not able to present NY-ESO-188–96. We further excluded HLA-
Cw7 as the restriction allele using NY-ESO-188–96-pulsed LCL
that only shared HLA-Cw7 with the patient, which did not
activate the TCD8+ line (data not shown), and concluded that
HLA-B*1801 presented NY-ESO-188–96.
Having shown that the NY-ESO-188–96-specific TCD8+ response
is HLA-B18-restricted, and is immunodominant in patient 8, we
investigated whether this response was induced by vaccination. We
expanded T cells from PBMC of patient 8 collected before or 70
days after vaccination. Although the response to HLA-B18/NY-
ESO-188–96 was detectable in the pre-vaccination PBMC sample
(0.19% of total TCD8+, Figure 2A), it was obviously boosted by the
NY-ESO-1 ISCOMATRIXTM vaccine (1.38% of total TCD8+ post
vaccination, Figure 2A). We then examined whether a similar
response can be found in PBMCs from other melanoma patients
who also express HLA-B18 and had anti-NY-ESO-1 antibody
response, which is often associated with anti-NY-ESO-1 T cell
response [27]. Antigen-specific TCD8+ were expanded using NY-
ESO-179–91 peptide and then assessed their antigen-specificity
using both tetramer and intracellular cytokine staining (ICS) for
IFN-c. As shown in Table 1, among eight other HLA-B18+
patients, three of the patients had detectable TCD8+ specific for
HLA-B18/NY-ESO-188–96. Interestingly, all three were inciden-
tally placed in the vaccine groups and the responses were pre-
existed before vaccination, indicating that the response we
detected in patient 8 is not a single case and the anti-NY-ESO-
188–96 response is likely the immunodominant response associated
with HLA-B18. However, the other five samples showed no
detectable response to this epitope.
To further characterize this immunodominant T cell response,
we conducted a T cell repertoire analysis on TCD8+ specific to
HLA-B18/NY-ESO-188–96 in PBMCs from patient 8. While the
majority of T cells used Vb3.1, 5a, 8a and 13, other Vb chains
were also used by the antigen-specific TCD8+ (Figure 2B),
indicating that the NY-ESO-188–96-specific TCD8+ lines used in
this study are of polyclonal nature.
A CD8+ Epitope Crosspresented from Soluble Antigen
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e44707
NY-ESO-188–96-specific TCD8+ do not Recognize
Melanoma Cell Line SK-MEL-8
We have so far shown that the NY-ESO-188–96-specific TCD8+
in most patients were spontaneously generated and can be boosted
by vaccination with NY-ESO-1 ISCOMATRIXTM vaccine. It is
important to find out whether these TCD8+ are able to recognize
tumor cells. To this end, we expanded TCD8+ lines either specific
to HLA-B18/NY-ESO-188–96, or HLA-A2/NY-ESO-1157–165, a
well characterized and naturally presented epitope to serve as a
positive control [3,29]. The two TCD8+ lines were then used to
detect direct antigen presentation on a melanoma cell line, SK-
MEL-8, which expresses NY-ESO-1 as well as HLA-B18 and
HLA-A2. HLA-B18/NY-ESO-188–96 and HLA-A2/NY-ESO-
1157–165 tetramers were used in combination with ICS for IFN-c
to positively identify the antigen-specific TCD8+ [30]. As expected,
peptide-pulsed HLA-B18+ and HLA-A2+ LCL line 9039 (not
shown) and SK-MEL-8 induced IFN-c production from most of
the tetramer+ TCD8+ specific to either epitope (Figure. 3A left
panels). Importantly, more than half (50.3% and 52.2%) of the
NY-ESO-1157–165 specific TCD8+ were stimulated to produce IFN-
c by co-culture with SK-MEL-8 tumor cells regardless of the 48
hour IFN-c induction (Figure. 3A middle and right panels).
However, NY-ESO-188–96 specific TCD8+ did not respond to the
same APCs (Figure. 3A top panels), despite higher avidity for
HLA-B18/NY-ESO-188–96 compared to the TCD8+ specific to
HLA-A2/NY-ESO-1157–165 (Figure. 3B), indicating that either
HLA-B18/NY-ESO-188–96 is not directly presented or not
presented in sufficient quantity by this tumor line, as required to
trigger the antigen-specific TCD8+.
Presentation of NY-ESO-188–96 is Immunoproteasome-
dependent and Requires Higher NY-ESO-1 Expression
It is well established that IFN-c treatment of cell lines lead to
enhanced antigen processing and presentation, as IFN-c up-
regulates MHC class I expression and switches constitutive
proteasome to immunoproteasome [31].
The apparent lack of endogenous presentation of HLA-B18/
NY-ESO-188–96 by this tumor cell line was further investigated, in
combination with IFN-c treatment, using the following two
strategies to enhance NY-ESO-1 expression. Firstly, we treated
Figure 1. Identification and characterization of a novel NY-ESO-1 TCD8+ epitope. A. PBMCs were collected from patient 8 on day 70
following vaccination with NY-ESO-1 ISCOMATRIXTM vaccine. These cells were cultured with a panel of overlapping NY-ESO-1 18 mer peptides and
then tested for responsiveness to each peptide in an ICS assay for IFN-c. Because the background to control peptides was negligible, the results from
individual cultures were plotted as a single combined figure. B, C, TCD8+ line expanded with NY-ESO-179–96 18 mer was tested under FCS-free
condition for its reactivity to various HPLC-purified peptides (B) and the minimum peptide NY-ESO-188–96 at various peptide concentrations (C). D, a
panel of LCL lines sharing HLA alleles with patient 8 were pulsed with the minimum NY-ESO-188–96 peptide, extensively washed, co-cultured with NY-
ESO-188–96-specific TCD8+ line and followed with ICS.
doi:10.1371/journal.pone.0044707.g001
A CD8+ Epitope Crosspresented from Soluble Antigen
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tumor line SK-MEL-8 with DNA hypomethylation agent 5-aza-2-
deoxycytidine (5-aza-dC), which has been reported to upregulate
cell surface class I and induce or upregulate the expression of
different CT antigens in cultured human melanoma lines [32].
Secondly, we infected the cell line with recombinant vaccinia
viruses encoding NY-ESO-1 (rVV-NY-ESO-1), which was
expected to boost NY-ESO-1 expression. As shown in Figure 4A,
the IFN-c treatment increased cell surface class I expression by
two fold for SK-MEL-8. However, 5-aza-dC treatment did not
increase class I expression. We also performed the treatment under
various concentration of 5-aza-dC and similar results were
obtained (data not shown). We next used Western blotting to
assess the changes in the expression of NY-ESO-1 and the
immunoproteasome subunits for the tumor cell line after these
treatments. As shown in Figure 4B, SK-MEL-8 expressed NY-
ESO-1 at a level that was readily detected and was not further
induced by 5-aza-dC treatment. IFN-c treatment did not enhance
NY-ESO-1 expression although it clearly induced the expression
of the immunoproteasome subunit LMP2, LMP7 and MECL-1
(Figure 4B) indicating the switching over from constitutive
proteasome to immunoproteasome. Of note, there are faint,
similar sized bands revealed by both anti-LMP2 and anti-LMP7
anti-sera before IFN-c treatment. It is possible that these cells may
express low level of these subunits under normal culture condition.
As expected, rVV-NY-ESO-1 infection of the tumor line greatly
boosted NY-ESO-1 expression (,6-fold increase according to the
analysis performed using ImageQuant TL software, Amershan
Biosciences, data not shown). Importantly, the above-described
changes were treatment-specific because the internal loading
control of each sample, b-actin, remained unchanged (Figure 4B
top and data not shown).
Using similar T cell lines as shown in Figure 3, we tested the
above treated SK-MEL-8 cells for their antigen presenting
capacity. NY-ESO-1157–165 was again efficiently presented without
the treatments. However, the IFN-c-treated SK-MEL-8 showed
enhanced antigen-presenting capacity for NY-ESO-1157–165
Table 1. TCD8+ response to HLA-B18/NY-ESO-188–96.
Group Patients HLA
Tetramer or ICS (% of total
CD8+ T cells) Vaccination status
HLA-A HLA-B HLA-C Pre-vac Post-vac
NY-ESO-1 ISCOMATRIXTM
Vaccine
8 A68 B1801, B4402 Cw5, Cw7 0.19 1.220 Boosted
111 A2, A3 B1801, B5101 Cw1,Cw7 2.87 3.76 Pre
102 A3, A11 B1801, B4403 Cw7,Cw16 3.89 4.76 Pre
109 A2 B1801, B4402 Cw5,Cw7 0.140 0.140 Pre
12 A25, A68 B1801, B1402 Cw7,Cw8 ND –*
Placebo controls 115 A2, A30 B1801, B3901 Cw5 ND –*
114 A2, A25 B1801, B3701 Cw6 ND –*
29 A1, A31 B18, B27 Cw2,Cw6 ND –*
113 A3, A25 B18, B7 Cw7, ND –*
Melanoma patients from three clinical trials (see Materials and Methods) with detectable anti-NY-ESO-1 antibody responses and HLA-B18 expression were selected for
the screen. T cells from PBMC samples post vaccination (or placebo controls that did not receive the NY-ESO-1 ISCOMATRIXTM vaccine but received diluents) were
expanded with 18 mer NY-ESO-179–96 peptide for 12,15 days and assessed with NY-ESO-188–96 in an ICS assay (only ICS results ,0.1% are shown as negative ‘‘–’’
indicated by ‘*’). For patients who showed positive TCD8+ response to this epitope (.0.1%, data not shown) in their post vaccination samples, pre- and post-vaccination
PBMC samples were then expanded the same way side-by-side in a second screen intended to determine whether the response was a result of the vaccination. The
peptide-specific TCD8+ in the second screen were assessed with the specific HLA-B18/NY-ESO-188–96 tetramer. Tetramer results.0.1% of total CD8
+ T cells with a discrete
staining pattern are shown; and those results ,0.1% are shown as ‘‘-’’. Pre – pre-existed response; Boosted – vaccine-boosted response; ND – not determined, Pre-vac,
prior to vaccination; Post-vac, after vaccination.
doi:10.1371/journal.pone.0044707.t001
Figure 2. NY-ESO-188–96-specific T cells are vaccine boosted
and utilize polyclonal T cell receptors. PBMCs from patient 8
collected before (day 0) and after (day 70) vaccination with NY-ESO-1
ISCOMATRIXTM vaccine were expanded with 18 mer NY-ESO-179–96 and
the T cells were assessed by ICS (A). A similar T cell line expanded from
day 70 PBMC sample from patient 8 was first stimulated with NY-ESO-
188–96 peptide, then split into multiple wells and stained with anti-CD8
and a panel of antibodies specific to various TCR Vb families separately,
followed with ICS for IFN-c (B). Graph indicates the percentage of NY-
ESO-188–96-specific (IFN-c-producing) T cells expressing the indicated
TCR Vb families.
doi:10.1371/journal.pone.0044707.g002
A CD8+ Epitope Crosspresented from Soluble Antigen
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(Figure 5A). By contrast, the HLA-B18/NY-ESO-188–96 specific
TCD8+ were not activated by the same cells, unless they were both
IFN-c-treated and rVV-NY-ESO-1 infected (Figure 5A and the
FACS plots in Figure 5B correspond to IFN-c-induced SK-MEL-8
that were either uninfected or infected with rVV-NY-ESO-1 or
rVV-GFP). These data imply that the NY-ESO-188–96 epitope was
processed inefficiently from endogenous antigen and the process-
ing relied on the action of the immunoproteasome rather than the
constitutive proteasome.
NY-ESO-188–96 is Directly Presented by Tumor Cells
Expressing High Level of Immunoproteasome
To exclude the possibility that the above results were the biased
outcome of a single melanoma line SK-MEL-8, we collected four
other HLA-B18 expressing melanoma lines (for detailed HLA class
I typing information, please see Table S1). These lines were again
left untreated or treated with IFN-c to induce both immunopro-
teasome and cell surface class I expression; or after IFN-c-
induction the cells were further infected with rVV-NY-ESO-1 to
either induce or enhance NY-ESO-1 expression. As IFN-c can
induce many changes in gene expression, the changes of the
immunoproteasome in these cell lines were further monitored
functionally by the change of antigen presentation for the HLA-
A2/Melan A26–35 epitope as its presentation was reported
previously to be impaired by the immunoproteasome [15]. As
shown in Figure 6A, although LM-MEL-59, SK-MEL-8 and SK-
MEL-25 all expressed NY-ESO-1 antigen and B*1801, they did
not present NY-ESO-188–96, unless they are both IFN-c-induced
and infected with rVV-NY-ESO-1. This recognition also critically
depends on the high avidity of NY-ESO-188–96-specific T cell line
as a lower avidity line failed to do so (Figure S1A, B). The
recognition is not an artifact of rVV infection as the same tumor
line transiently transfected with pcDNA3-NY-ESO-1 during IFN-
c-induction also presented this epitope (Figure S1C). However,
SK-MEL-44 was not able to present NY-ESO-188–96, even under
the same treatment regime with similar HLA expression level. It is
highly likely that the single AA substitution in B*1803 (Y74D) from
B*1801, which is located on the a1-helixes of the peptide-binding
cleft, had either prevented NY-ESO-188–96 from binding B*1803
or the T cells from recognizing B*1803/NY-ESO-188–96.
Overall, most tested melanoma cell lines expressed detectable
immunoproteasome subunit LMP2 and LMP7 although at
relatively low level (Figure 6B). Interestingly, the cell line LM-
MEL-51 presented NY-ESO-188–96 quite efficiently even when it
was not treated with IFN-c although rVV-NY-ESO-1 infection
did further enhance the presentation. However, this cell line
expressed high level of LMP2 and LMP7 under normal cell
culture conditions and the IFN-c induction did not further induce
such expression significantly (Figure 6B). Of note, the immuno-
proteasome expression level in LM-MEL-51 in the absence of
IFN-c-induction seemed to be even higher than that of other lines
after IFN-c-induction. Importantly, as an internal control the
presentation of Melan A26–35 by the three HLA-A2 positive cell
Figure 3. NY-ESO-188–96 is not naturally presented by melanoma cells. A, NY-ESO-1157–165– and NY-ESO-188–96–specific TCD8+ lines were
expanded from PBMCs collected from the previously reported patient 7 [6] and patient 8 with 18 mer peptides NY-ESO-1157–174 and NY-ESO-179–96
respectively. These T cells were then co-incubated with tumor line (SK-MEL-8) with or without a 48 hr IFN-c induction (seeMaterials and Methods
for details). The untreated SK-MEL-8 cells were also pulsed with both peptides followed by washing out excessive peptides to serve as a maximum
antigen presentation control. Antigen-specific T cell activation was then revealed by tetramer and IFN-c double staining. Percentage represents
antigen-specific, IFN-c-producing cells amongst total tetramer positive cells (note, the double negative cell population was not included in the
percentage calculation). B, the same TCD8+ lines used in A were also assessed for their affinity by peptide titration. Percentage represents Ag-specific T
cells among total CD8+ T cells. Similar data were obtained from three similar experiments.
doi:10.1371/journal.pone.0044707.g003
A CD8+ Epitope Crosspresented from Soluble Antigen
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lines were easily detected and decreased after IFN-c-induction,
confirming their impaired presentation by the immunoproteasome
reported by Morel et al [15] and further implying the induction of
the immunoproteasome by IFN-c treatment. It is not clear why
LM-MEL-51 did not present NY-ESO-1157–165 as well as SK-
MEL-8 although the former expressed higher level of HLA-A2
(Figure 6C and Figure S1B). It is possible that the direct
presentation of NY-ESO-1157–165 requires the activity of the
constitutive proteasome, perhaps even more so than that required
by the Melan A26–35. Taken together, the direct presentation of
NY-ESO-188–96 by melanoma lines requires high level of both
immunoproteasome and NY-ESO-1 expression by tumor lines.
NY-ESO-188–96 is Efficiently Cross-presented by MoDC
Knowing that the HLA-B18/NY-ESO-188–96 response is often
detectable in melanoma patients and that anti-tumor immunity
relies on cross-presentation, we hypothesized that this epitope is
efficiently cross-presented by DCs. Our previous studies have
shown that the antigen formulations influence the efficiency and
the pathways of antigen processing and cross-presentation
[3,21,28]. To investigate the cross-presentation of NY-ESO-188–
96 from full-length antigen, MoDCs expressing both HLA-B*1801
and HLA-A*0201 were incubated overnight in the presence of
different NY-ESO-1 antigen formulations including soluble NY-
ESO-1 protein, NY-ESO-1 ISCOMATRIXTM vaccine and NY-
ESO-1/IC and subsequently co-cultured with TCD8+ lines specific
to either HLA-A2/NY-ESO-1157–165 or HLA-B18/NY-ESO-188–
96. TCD8+ activation was again enumerated with tetramer and
ICS. As shown in Figure 7A, 15 to 30% of NY-ESO-1-specific
TCD8+ were activated by NY-ESO-1/IC and NY-ESO-1 ISCO-
MATRIXTM vaccine, respectively for the two TCD8+ lines,
although the NY-ESO-1157–165 epitope was cross-presented
slightly more efficiently than NY-ESO-188–96. Few T cells of the
TCD8+ line specific to HLA-A2/NY-ESO-1157–165 were activated
by the MoDCs incubated with soluble NY-ESO-1 protein. By
contrast more than 60% of NY-ESO-188–96 specific TCD8+ were
activated by the same MoDCs incubated with the soluble NY-
ESO-1 protein. We further demonstrated that these MoDCs first
took up the soluble NY-ESO-1 protein followed by endogenous
antigen processing to present these epitopes; because under the
same conditions with BFA addition, which prevents the HLA from
Figure 4. IFN-c-induction induces immunoproteasome and
rVV-NY-ESO-1 infection significantly increases NY-ESO-1 ex-
pression in tumor cells. Tumor cell line, SK-MEL-8, was treated with
either IFN-c for 48 hrs or 5-aza-dC for 72 hrs. The cells were then
stained for their surface class I expression (A). The treated cells were
also infected with rVV-NY-ESO-1, or rVV-GFP as a control, for 4 hours.
The infected and uninfected cells were then lysed immediately for
Western analysis (B). Similar data were obtained from three similar
experiments. Note, b-actin was reblotted after stripping the previously
bound anti-NY-ESO-1 antibody.
doi:10.1371/journal.pone.0044707.g004
Figure 5. NY-ESO-188–96 is poorly presented directly by tumor
cells. In A and B, Tumor cells were treated as described in Figure 4. The
treated tumor cells were then co-cultured with T cell lines specific for
NY-ESO-1157–174 and NY-ESO-188–96 as described in Figure 3. The purity
of the TCD8+ lines were .70% (data not shown). The antigen
presentation results are shown in A and the FACS plots corresponding
to NY-ESO-188–96 TCD8+ responses to IFN-c treated SK-Mel-8 are shown
in B (shown by the arrow). Similar data were obtained from three similar
experiments.
doi:10.1371/journal.pone.0044707.g005
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Figure 6. NY-ESO-188–96 is directly presented by tumor cells expressing high level of immunoproteasome. Five melanoma lines,
including SK-MEL-8, were left untreated or treated with either IFN-c for 48 hrs or were further infected with rVV.NY-ESO-1 for 5 hrs. The tumor cells
were then co-cultured with T cell lines specific for NY-ESO-1157–174, NY-ESO-188–96 and Melan A26–35 as described in Figure 3. The purity of the TCD8+
lines were 42%, 88% and 68% respectively (data not shown). The antigen presentation results are shown in A and the western blot results for LMP2,
LMP7 and the loading control GAPDH for the corresponding tumor lines and the treatment conditions are shown in B. The FACS analysis results of
the cell surface HLA molecules as Mean Channel Fluorescence intensity (MCF) are shown in C. The MCF values for HLA-A2 and B18 were about 100 for
the FITC-conjugated secondary antibody alone; and those values for the All Class I group for the PE-conjugated secondary antibody alone were about
300. Similar data were obtained from three similar experiments.
doi:10.1371/journal.pone.0044707.g006
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leaving the endoplasm reticulum, cross presentation was abolished
(Figure 7B). This indicated that in our system the NY-ESO-188–96
peptide was generated intracellularly after antigen uptake and not
extracellularly by serum proteases. We attempted incubating NY-
ESO-1+ tumor cell lysates with MoDCs in such assays with no
success (data not shown). We believe that the NY-ESO-1 protein
amount might be too little relative to the total cellular protein
amount in the tumor lysates.
Discussion
In the process of monitoring T cell responses induced by the
NY-ESO-1 ISCOMATRIXTM vaccine, we identified a novel NY-
ESO-188–96 epitope presented by HLA-B18 molecule. The
polyclonal TCD8+ response to this epitope was immunodominant
in PBMC from patient 8 and was clearly boosted by our
vaccination. The NY-ESO-188–96 peptide was efficiently cross-
presented by MoDCs pulsed with soluble, recombinant NY-ESO-
1 protein, which is different to what has been found for other NY-
ESO-1-derived TCD8+ epitopes [3,21,28].
It is well established that direct antigen presentation typically
requires ongoing antigen synthesis and proteasome-mediated
degradation [16,17]. However, cross-presentation does not require
sustained antigen synthesis and degradation in antigen-donating
cells [19]. Given these contrasting requirements between the two
presentation pathways and taking into account the peptide
cleavage preferences for the constitutive proteasome and the
immunoproteasome respectively, there has been surprisingly no
reported example demonstrating differential cross- and direct-
presentation in human APC. Ochsenbein et al [33] showed that,
in an artificial tumor antigen system in mice, there was direct
priming in the absence of detectable cross-priming for the LCMV-
derived GP33 epitope expressed on either fibroblasts or EL-4
thymoma cells. In this system, syngeneic tumor cells were used and
it was not clear whether or not priming relied on cross-
presentation by DCs. Consequently, these authors questioned
the physiological significance of cross-presentation in anti-tumor
and anti-viral immune responses [33]. In an HLA-A2 transgenic
mouse model, Chapatte et al showed that only immunoprotea-
some deficient DCs were able to prime TCD8+ response to a
melanoma differentiation antigen Melan A [34]. However, in this
system DCs were infected with a non-replicative lentivirus
expressing Melan A before being transferred into naı¨ve mice.
Therefore, potentially only direct antigen presentation and
priming were assessed, which is likely not the major role DCs
play in anti-tumor immunity [34]. Our results clearly demonstrat-
ed that cross-presentation of tumor antigens, such as NY-ESO-
188–96, occurs readily in cultured MoDCs, especially from soluble
form of NY-ESO-1. We are not aware of any other T cell epitope
that is more efficiently cross-presented from soluble antigen than
complexed antigen forms. This is likely also the case in vivo,
because among the nine melanoma patients screened in our study,
four had detectable HLA-B18/NY-ESO-188–96 responses, while
there was no direct presentation of this epitope by most melanoma
cells tested. The same melanoma cells were able to present NY-
ESO-1157–165 efficiently under the same conditions (Figure 5, 6,
and Figure S1B, C) indicating that the amount of NY-ESO-1
expressed by the tumor lines is physiologically sufficient and the
antigen processing and presentation machinery is normal. Judging
from the NY-ESO-1 amount after rVV-NY-ESO-1 infection
(Figure 4B), with more than 6-fold increase in expression in the
infected SK-MEL-8, it is inconceivable that such level of NY-
ESO-1 expression might be achieved in vivo under physiological
conditions. Therefore, it is difficult to envisage that the HLA-B18/
NY-ESO-188–96 epitope would be ever presented in sufficient level
directly on tumor cell surface unless there was a concomitant
infection in the tumor-bearing host and the infection resulted in
sufficient IFN-c production to induce immunoproteasome in these
cells. Interestingly, one of the melanoma lines tested, LM-MEL-
51, expressed high level of immunoproteasome and directly
presented NY-ESO-188–96 (Figure 6A). However, it is not clear
whether such property was developed in vivo or in vitro. These
results not only indicate that the two NY-ESO-1-derived epitopes
are processed and presented differently by the intracellular antigen
processing and presentation machinery, for both direct- and cross-
presentation; but also provide strong evidence that some of the
epitopes may not serve as direct target on tumor cells.
Figure 7. NY-ESO-188–96 is cross-presented efficiently by DCs
from soluble antigen. In A, MoDCs expressing both HLA-A2 and HLA-
B18 were cultured for 7 days, and then incubated overnight under the
indicated conditions before being co-cultured with the indicated TCD8+
lines for 5 hrs in the presence of BFA. NY-ESO-1 specific TCD8+ activation
was assessed by tetramer and ICS. IFN-c producing cells out of total
antigen-specific (tetramer positive) TCD8+ were converted to percent-
ages of maximum activation induced by the respective minimum
peptide (peptide activation of NY-ESO-1157–174 TCD8+ line and NY-ESO-
179–96 TCD8+ line were both 30% to 45% for all three experiments
conducted, data not shown) and plotted as ‘‘% Maximum activation’’.
After data conversion, mean values and standard deviations were
calculated from data obtained from three similar experiments. In B, one
of the control experiments was shown for APCs that were either pulsed
with the corresponding peptide or soluble NY-ESO-1 for one hour
followed with BFA addition to demonstrate the nature of intracellular
cross-presentation for both TCD8+ epitopes without affecting extracel-
lular peptide presentation. Similar results were obtained twice.
doi:10.1371/journal.pone.0044707.g007
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In patients with such T cell responses, the tumor cells would
therefore behave as natural immune escape mutants, much the
same as those that have down regulated their MHC class I
expression and lost their antigen-presentation capacity [22,35].
However, the key difference here maybe that the antigen is likely
efficiently taken up by tumor stroma cells (including DCs,
macrophages and perhaps others) and the TCD8+ epitopes are
then more efficiently displayed. It is not yet known whether stroma
elimination by such TCD8+ would be beneficial in humans.
However, Spiotto et al. recently demonstrated that murine tumor
cells lacking antigen-presenting MHC molecules were controlled
by TCD8+ specific for antigens expressed by these tumor cells
through the elimination of stroma cells that cross-presented the T
cell epitopes from the same tumor antigens [36]. Tumor stroma
has been known to play a major role to support tumor growth and
sometimes to suppress the immune system [37]. It is therefore
possible that TCD8+ specific for epitopes that are efficiently cross-
presented might actually play an important role, albeit indirect, to
keep tumors in check.
On the other hand, if such TCD8+ responses are immunodo-
minant, such is the case in our patient 8, the subdominant yet
tumor-recognizing TCD8+ responses may not be efficiently
stimulated due to excess expansion of the immunodominant
TCD8+ and, as a result of that, elimination of the cross-presenting
DCs. Therefore, TCD8+ with this specificity will further expand
and prevent other potentially more beneficial, but subdominant
TCD8+ responses from being activated or expanded by the same
DCs, a phenomenon termed as immunodomination [23]. There is
an example in immunity against influenza A virus in C57BL/6
mouse model, in which vaccinating TCD8+ specific to the
immunodominant epitope from acidic polymerase PA224–233
caused delayed viral clearance, because this epitope is only
generated by DCs [38,39] due to its strict immunoproteasome
dependence [13,14].
Biased differential antigen presentation by either the immuno-
proteasome or the constitutive proteasome has been reported for
directly presented, tumor derived epitopes [15,34,40,41]. It has
also been recently shown that human MoDCs were more capable
of presenting T cell epitopes from melanoma antigens when
immunoproteasome expression was knocked down by small
interference RNA (siRNA) [42]. However, the later study
investigated T cell responses in already ‘primed’ melanoma
patients and did not directly address the role of DC’s cross-
presentation in anti-tumor immunity, because the tumor antigens
studied were all introduced into these DCs by RNA transfection
[42]. Our study demonstrated a near ‘black-and-white’ outcome
between direct- and cross-presentation for the NY-ESO-188–96
epitope unless high level immunoproteasome is expressed by
tumor cells. Importantly, our results may indicate the existence of
a whole group of TCD8+ epitopes resulted from differential antigen
processing and presentation between DCs and tumor cells. As NY-
ESO-188–96-specific T cells are naturally primed and immunodo-
minant in the melanoma patient 8 examined in detail in our study,
our findings have important implications for future vaccine design.
For example, it might be desired to avoid priming or boosting such
TCD8+ by using mutated NY-ESO-1. For instance mutating the
anchor residues (89E or 96F) to an Alanine for the NY-ESO-188–96
epitope would abrogate the stimulation of its specific TCD8+.
Alternatively, using an antigen form rather than the soluble one
may minimize the stimulation to these TCD8+ if their expansion
results in immunodomination. Conversely, if these TCD8+ play a
positive role through the elimination of stroma cells, as reported in
the above mentioned murine system, vaccination with either the
soluble form of NY-ESO-1 or the minimal peptide NY-ESO-188–
96 would then be ideal. Therefore, using full-length tumor antigen
as vaccine, although potentially providing broader coverage for T
cell epitopes and HLA polymorphism as it may provide all the
available epitopes, could be an over-simplified strategy due to the
lack of consideration on differential direct- and cross-presentation,
not to mention it does not avoid stimulating potential antigen-
specific regulatory T cells [43].
Materials and Methods
Patients
Melanoma patients (listed in Table 1) were vaccinated by
intramuscular injection with 100 mg NY-ESO-1 ISCOMA-
TRIXTM vaccine from LUD99-008 [6] or LUD2002-013
(ClinicalTrials.gov Identifier: NCT00518206) and LUD2003–
013 [44]. The LUD99-008 study included patients who received
placebo or NY-ESO-1 protein alone and showed that these
cohorts were not effectively vaccinated. All studies were approved
by the Human Research Ethics Committees of Austin Health and
the Peter MacCallum Cancer Center. All patients provided
written informed consent.
Peptides, Antibodies, Tetramers and NY-ESO-1
Formulations
NY-ESO-1 overlapping 18 mers, 9mers (88–96 (LEFYLAMPF)
and 157–165 (SLLMWITQC)) and shorter peptides and Melan
A26–35 (EAAGIGILTV) were synthesized by Auspep (Mel-
bourne, Australia). Monoclonal antibodies to CD8, CD4, IFN-c
and HLA class I (W6/32) were purchased from BD (Franklin
Lakes, NJ) and the anti-HLA-A2 (BB7.2), Bw6 (which recognizes
B18 and a few other HLA-B alleles) were used as hybridoma
culture supernatants. PE-conjugated HLA-B18/NY-ESO-188–96
and HLA-A2/NY-ESO-1157–165 tetramers were synthesized at the
Tetramer Production Facility of the Ludwig Institute for Cancer
Research (Lausanne, Switzerland). Flow cytometry was performed
using a BD FACSCalibur or FACSCanto II instrument, and data
were analyzed using FlowJo software (TreeStar Inc., Ashland,
OR).
Full length recombinant NY-ESO-1 protein was produced in E
coli and purified in the GMP facility of the Ludwig Institute for
Cancer Research at the Memorial Sloan-Kettering Cancer Center
(New York, USA). Endotoxin levels ranged between 3–31 EU/
0.1 mg of protein (limit ,175 EU/0.1 mg protein). ISCOMA-
TRIXTM adjuvant (CSL Limited, Victoria, Australia) formulated
NY-ESO-1 was generated as described [45,46]. Immune com-
plexes (ICs) (NY-ESO-1/IC) were generated by mixing NY-ESO-
1 protein with anti-NY-ESO-1 mAb ES121 at a 1:2 molar ratio in
serum-free RPMI-1640 at 37uC for 30 min as previously described
[3].
Cell Lines, MoDCs, T Cell Culture and Media
All cell lines are maintained in complete medium RF-10
consisting of RPMI-1640 supplemented with 2 mM Glutamax,
antibiotics, 10 mM HEPES (Invitrogen, Carlsbad, CA), 1% non-
essential amino acids and 10% fetal calf serum (FCS, Thermo
Trace, Melbourne, Australia). The SK-MEL-8, SK-MEL-25 [47]
and SK-MEL-44 [48] melanoma lines were obtained from the
Memorial Sloan-Kettering Cancer Center. LM-MEL-51 and LM-
MEL-59 melanoma cell lines were established in our laboratory
from melanoma biopsies. Epstein-Barr virus (EBV) transformed,
homozygous LCL 9010, 9063 and 9039 were made available from
the 10th International HLA Workshop (New York). PBMCs were
prepared from whole blood by Ficoll-Paque centrifugation. T cell
lines were generated using RF-10 containing 25 U/ml interleukin-
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2 (IL-2, Cetus, Emeryville, CA). PBMC from melanoma patients
expressing HLA-A2 and HLA-B18 and previously vaccinated with
NY-ESO-1 ISCOMATRIXTM vaccine were stimulated with
18 mers NY-ESO-179–96 (GARGPESRLLEFYLAMPF contain-
ing NY-ESO-188–96) and NY-ESO-1157–174
(SLLMWITQCFLPVFLAQP containing NY-ESO-1157–165) at
561026 M for 1 hour at room temperature [49]. T cell lines
were used at least 12 days after culture. In some cases, tetramer
enriched antigen-specific T cells were further expanded by PHA
and allogeneic feeders. T cell specificity was confirmed by tetramer
staining. For the 18 mer screen, PBMC from patient 8, post-
vaccination (70 days) with NY-ESO-1 ISCOMATRIXTM vaccine,
were cultured for 13 days with pooled overlapping NY-ESO-1
18 mer peptides (3 or 4 peptides per pool) and then tested for
responsiveness to individual 18 mer peptide within the pool by
ICS for IFN-c [50]. Pre- and post-vaccination PBMCs from
patients who received NY-ESO-1 ISCOMATRIXTM vaccine
were also tested in parallel to determine whether the B18-
restricted, NY-ESO-188–96-specific response was vaccinated or
occurred naturally. MoDC were generated from CD14+ mono-
cytes enriched by MACS beads (Miltenyi Biotec, Auburn, CA) in
the presence of 10 ng/mL IL-4 and 20 ng/mL GM-CSF for 6
days [3].
IFN-c and 5-aza-2-deoxycytidine Treatment of Tumor Cell
Line
The melanoma cell line was cultured in either RF-10 or RF-10
plus 50 ng/ml recombinant human IFN-c (PeproTech) for 48 hrs
before being used as APCs. 5-aza-2-deoxycytidine (5-aza-dC) was
purchased from Sigma-Aldrich. Melanoma cells were pulsed with
0.5 mM 5-aza-dC every 24 h for 3 days as previously described
[32], then used for the indicated experiments and for FACS
assessment of their surface Class I molecules using mouse
monoclonal antibodies (as hybridoma culture supernatants)
BB7.2 (HLA-A2), Bw6 (B18) and W6/32 (pan-class I molecules).
FITC conjugated secondary antibody was used for BB7.2 and Bw6
and PE-conjugated secondary antibody was used for W6/32
readout.
Antigen Pulsing and Recombinant Vaccinia Virus
Infections
For peptide pulsing, cells were incubated with 1026 M peptide
for 1 hour at room temperature, washed extensively before being
incubated with specific TCD8+. Recombinant vaccinia virus (rVV)
encoding NY-ESO-1 (rVV-NY-ESO-1) or Green Fluorescent
Protein (rVV-GFP) were gifts from Dr. Lloyd Old (Ludwig
Institute for Cancer Research, New York, USA) and Drs Jonathan
Yewdell and Jack Bennink (National Institute of Health, Bethesda,
Maryland, USA), respectively. Cells were incubated with rVV at a
multiplicity of infection (MOI) of 10 for 4 hours at 37uC. Infected
cells were then incubated with TCD8+ lines for antigen presentation
readout.
Western Blotting
Cells were lysed in 1% Triton-X (Sigma-Aldrich), and SDS-
PAGE analyses were performed. The proteins were transferred
electrophoretically to a polyvinylidene difluoride membrane
(Millipore). Separate Western blots were performed for NY-
ESO-1, LMP2, LMP7 and MECL-1 expression. All blots used
either b-actin or GAPDH as loading control. After transfer, the
membranes were incubated with the primary anti-b-actin or
GAPDH (abcam) plus anti-NY-ESO-1 mAb (ES121, [50]), or the
anti-LMP2 polyclonal rabbit anti-serum (abcam), or the anti-
LMP7 polyclonal rabbit anti-serum (abcam), or the anti-MECL-1
polyclonal rabbit anti-serum (BIOMOL) at 4uC overnight. All
anti-sera were used at 1:2000 dilutions. The membranes were
washed in PBS, peroxidase-labeled sheep anti-rabbit immuno-
globulins or sheep anti-mouse immunoglobulins for NY-ESO-1
(Silenus Labs) were added at a 1/2500 dilution in PBS with 0.05%
Tween 20. After further washing, the proteins were visualized
radiographically using an electrochemiluminescence (ECL Plus)
substrate (Amersham Biosciences) using a STORM phosphoima-
ger.
T Cell Function Assay
ICS was used in combination with tetramer staining as
previously reported by our group [30]. Briefly, cultured T cells
were re-stimulated with peptides for 4 hours in the presence of
10 mg/mL Brefeldin A (BFA, Sigma-Aldrich). The cells were then
stained with tetramer, anti-CD4 and anti-CD8, fixed with 1%
paraformaldehyde (ProSciTech, Queensland, Australia) and fur-
ther stained with anti-IFN-c in the presence of 0.2% saponin
(Sigma-Aldrich). Up to 30,000 events were recorded on a FACS
instrument and analyzed using FlowJo software.
For peptide titrations, 105 cultured T cells were incubated for 4
hours in the presence of 10 mg/mL BFA and serial dilutions of
peptide followed by ICS readout. In direct presentation assays,
105 T cells were co-cultured with 56104 tumor cells for 4 hours in
the presence of 10 mg/mL BFA followed by ICS readout. For cross
presentation, MoDCs were incubated overnight with 2 mg NY-
ESO-1 protein, NY-ESO-1 ISCOMATRIXTM vaccine or NY-
ESO-1/IC with 1 mg/mL CD40L-trimer (a kind gift from Amgen)
[3,28], in the presence or absence of 5 mg/mL BFA. Tetramer and
IFN-c double positive cells were used to calculate the percentages
of activated, antigen-specific TCD8+. Cells pulsed for 1 hour with
NY-ESO-188–96 peptide and washed before incubation with T
cells served as positive controls. For assessing TCR Vb usage of
peptide-specific TCD8+, peptide-expanded T cells from patient 8
were first activated with NY-ESO-188–96 peptide, then split into
multiple wells and stained with anti-CD8 and a panel of antibodies
specific to various TCR Vb families separately followed with ICS
for IFN-c.
Supporting Information
Figure S1 TCD8+ line from patient 102 is of lower avidity
and extra NY-ESO-1 expression via transfection also
enhances NY-ESO-188–96 presentation. T cell lines were
established using PBMC samples from Patient 8 or 102 under
similar conditions. The early cultures were then enriched through
tetramer-guided sorting and further expanded using PHA non-
specific stimulation. Various tumor lines were either untreated, or
treated for 48 hrs with IFN-c alone, rVV-NY-ESO-1 infected for
5 hrs, or doubly treated with IFN-c followed by rVV-NY-ESO-1
infection before being used as APC to stimulate T cell lines either
specific for A2/NY-ESO-1157–165 or B18/NY-ESO-188–96. In A,
peptide titration assay was performed by ICS without tetramer
staining. The purity of the T cell lines were: patient 8 NY-ESO-
188–96 line 88%; patient 102 NY-ESO-188–96 line 42%; and the
NY-ESO-1157–165 line 66%. B, for the direct presentation, ICS
combined with specific tetramer staining was conducted simulta-
neously as the titration assay shown in A. In C, SK-MEL-8 cells
were either untreated, or induce with IFN-c, or transiently
transfected (without selection) with pc3DNA-NY-ESO-1, 5 hrs
later induced with IFN-c for 48 hrs before being used as APC.
This was conducted on the same day using the same patient 8 NY-
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ESO-188–96 T cell line as that in A and B. Similar results were
obtained twice.
(TIF)
Table S1 Melanoma line HLA typing.
(DOC)
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